Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Christina Danial"'
Purpose: To assess the tumor response to the smoothened (SMO) inhibitor, sonidegib (LDE225), in patients with an advanced basal cell carcinoma (BCC) resistant to treatment with vismodegib (GDC0449).Experimental Design: Nine patients with an advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb24b0fc45b177f2527f2c303b066f4
https://doi.org/10.1158/1078-0432.c.6524225
https://doi.org/10.1158/1078-0432.c.6524225
Swimmer's plot showing resistance to vismodegib of study patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc734f23bc5eca7abbc639506c522628
https://doi.org/10.1158/1078-0432.22459463
https://doi.org/10.1158/1078-0432.22459463
functional resistance in vitro and SMO mutations found in study subjects. (a) SMO mutations with previously demonstrated functional resistance in vitro to Smoothened inhibitors, including vismodegib and sonidegib. Shaded cells indicate mutations that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8390917aa0da2467cc4f4a6f59974149
https://doi.org/10.1158/1078-0432.22459460
https://doi.org/10.1158/1078-0432.22459460
Publikováno v:
Pediatric Radiology. 49:1088-1103
Vascular anomalies can be correctly diagnosed in the majority of instances using the combination of clinical history, physical examination and imaging. In certain cases, the clinical work-up may be inconclusive or unavailable to the radiologist, and
Autor:
B A Rasidat Adeduntan, Amy S. Paller, Emily S. Gorell, Elena Pope, Kimberly D. Morel, Anne W. Lucky, Shufeng Li, Moise L. Levy, Elaine S. Gilmore, Alfred T. Lane, Anna L. Bruckner, B A Christina Danial
Publikováno v:
Pediatric Dermatology. 32:628-634
Pruritus is a common complication in patients with epidermolysis bullosa (EB). There is limited published data about the treatments that individuals with EB use for pruritus. The objective of the current study was to determine quantitatively which tr
Autor:
Alfred T. Lane, B A Rasidat Adeduntan, Elaine S. Gilmore, B A Christina Danial, Amy S. Paller, Elena Pope, Kimberly D. Morel, Anne W. Lucky, Moise L. Levy, Emily S. Gorell, Shufeng Li, Anna Bruckner
Publikováno v:
Pediatric Dermatology. 32:53-59
Qualitative data suggest that pruritus is a burdensome symptom in patients with epidermolysis bullosa (EB), but the prevalence of pruritus in children and adults with EB and factors that contribute to pruritus are unknown. The objective of the curren
Autor:
Thomas H. Leung, Alfred T. Lane, Joyce M.C. Teng, Christina Danial, Andrea L. Tichy, Phuong Khuu, Latanya Benjamin, Shreyas S. Vasanawala, Glenda L. Swetman, Umar Tariq
Publikováno v:
Journal of the American Academy of Dermatology. 70:1050-1057
Background Lymphatic malformations can be challenging to treat. Mainstay interventions including surgery and sclerotherapy are invasive and can result in local recurrence and complications. Objective We sought to assess the effect of 20 weeks of oral
Autor:
Raymond R. Balise, Anthony E. Oro, Bharathi Lingala, Christina Danial, A. Colevas, Sunil Reddy, Anne Lynn S. Chang
Publikováno v:
British Journal of Dermatology. 169:673-676
Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analys
Publikováno v:
Journal of Clinical Anesthesia. 22:519-526
To examine the relationship between body mass index (BMI), perioperative times, and anesthetic interventions in patients undergoing elective cesarean delivery.Retrospective chart review.University-affiliated hospital.All patients were ranked accordin
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(6)
Purpose: To assess the tumor response to the smoothened (SMO) inhibitor, sonidegib (LDE225), in patients with an advanced basal cell carcinoma (BCC) resistant to treatment with vismodegib (GDC0449). Experimental Design: Nine patients with an advanced